Drugs / IDP-118
last change Feb 2026 re-read 2 minutes ago

IDP-118

Developed for
psoriasis
Investigated by
Bausch Health Americas, Inc. · Dow Pharmaceutical Sciences

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03058744 Apr 2015 → Dec 2016 psoriasis Bausch Health Americas, Inc. Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT01670513 Jun 2012 → May 2013 psoriasis Dow Pharmaceutical Sciences Unknown No outcome recorded
Phase 22 trials
Phase 2 NCT02785172 Apr → Dec 2016 psoriasis Bausch Health Americas, Inc. Completed No outcome recorded
Phase 2 NCT02785159 Feb → Nov 2016 psoriasis Bausch Health Americas, Inc. Completed No outcome recorded
Phase 32 trials
Phase 3 NCT02462122 Aug 2015 → Nov 2016 psoriasis Bausch Health Americas, Inc. Completed No outcome recorded
Phase 3 NCT02462070 Aug 2015 → Nov 2016 psoriasis Bausch Health Americas, Inc. Completed No outcome recorded
Phase 41 trial
Phase 4 NCT03988439 Mar 2021 → Feb 2026 psoriasis Bausch Health Americas, Inc. Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as IDP-118 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02462070
6

NCT03058744

NCT02462122

NCT01670513

NCT02785172

NCT02785159

NCT03988439

Route Topical topical lotion” NCT02462070